Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

LUND, Sweden I July 1, 2025 I Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous ...

Tesamorelin, a synthetic growth hormone-releasing hormone (GHRH) analog, has garnered significant attention in scientific ...

Growth Hormone-Releasing Peptide-2 (GHRP-2) is a synthetic hexapeptide that has garnered significant attention in the ...

The type 1 insulin-like growth factor I (IGF-IR) receptor plays a significant role in the growth of normal and abnormal cells, and antibodies against the IGF-IR are now in clinical trials.

GLP-1 receptor agonists (GLP-1) are medicines that lower blood glucose levels and may also have beneficial effects on high blood pressure and obesity, and decrease the chances of death, heart attack, ...

The original methods for targeting the IGF-I receptor in experimental animals were antisense strategies and dominant-negative mutants of the receptor. They are obsolete. Several antibodies to the ...

In a paper published in Diabetes, they show that, in Type 1 diabetes patients, verapamil prevented the decline of the hormone insulin-like growth factor 1, or IGF-1, as compared to controls who did ...

Insulin and IGF-1, acting through the insulin receptor (IR) and IGF-1 receptor (IGF1R), maintain muscle mass and mitochondrial function, at least part of which occurs via their action to regulate gene ...

Inducible degradation of the insulin/insulin-like growth factor-1 receptor shows that a doubling in lifespan is possible even at extremely old ages in an organism.